Annual CFF
-$98.50 K
-$45.12 M-100.22%
December 31, 2023
Summary
- As of February 26, 2025, RLMD annual cash flow from financing activities is -$98.50 thousand, with the most recent change of -$45.12 million (-100.22%) on December 31, 2023.
- During the last 3 years, RLMD annual CFF has fallen by -$28.57 million (-100.35%).
- RLMD annual CFF is now -100.05% below its all-time high of $187.94 million, reached on December 31, 2021.
Performance
RLMD Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$89.60 K
-$89.60 K-100.00%
September 30, 2024
Summary
- As of February 26, 2025, RLMD quarterly cash flow from financing activities is -$89.60 thousand, with the most recent change of -$89.60 thousand (-100.00%) on September 30, 2024.
- Over the past year, RLMD quarterly CFF has dropped by -$311.30 thousand (-140.41%).
- RLMD quarterly CFF is now -100.06% below its all-time high of $161.84 million, reached on December 31, 2021.
Performance
RLMD Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$33.60 K
-$89.60 K-72.73%
September 30, 2024
Summary
- As of February 26, 2025, RLMD TTM cash flow from financing activities is $33.60 thousand, with the most recent change of -$89.60 thousand (-72.73%) on September 30, 2024.
- Over the past year, RLMD TTM CFF has dropped by -$89.60 thousand (-72.73%).
- RLMD TTM CFF is now -99.98% below its all-time high of $215.96 million, reached on March 31, 2022.
Performance
RLMD TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RLMD Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.2% | -140.4% | -72.7% |
| 3 y3 years | -100.3% | -148.4% | -99.9% |
| 5 y5 years | -100.6% | -107.7% | -99.8% |
RLMD Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.0% | at low | -100.1% | +9.0% | -100.0% | +134.1% |
| 5 y | 5-year | -100.0% | at low | -100.1% | +9.0% | -100.0% | +134.1% |
| alltime | all time | -100.0% | +64.0% | -100.1% | +17.9% | -100.0% | +111.8% |
Relmada Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$89.60 K(<-9900.0%) | $33.60 K(-72.7%) |
| Jun 2024 | - | $0.00(-100.0%) | $123.20 K(0.0%) |
| Mar 2024 | - | $221.70 K(-325.1%) | $123.20 K(-225.1%) |
| Dec 2023 | -$98.50 K(-100.2%) | -$98.50 K(<-9900.0%) | -$98.50 K(-124.0%) |
| Sep 2023 | - | $0.00(0.0%) | $409.90 K(-58.1%) |
| Jun 2023 | - | $0.00(0.0%) | $979.00 K(-93.5%) |
| Mar 2023 | - | $0.00(-100.0%) | $15.07 M(-66.5%) |
| Dec 2022 | $45.02 M(-76.0%) | $409.90 K(-28.0%) | $45.02 M(-78.2%) |
| Sep 2022 | - | $569.10 K(-96.0%) | $206.45 M(+0.2%) |
| Jun 2022 | - | $14.09 M(-52.9%) | $206.06 M(-4.6%) |
| Mar 2022 | - | $29.95 M(-81.5%) | $215.96 M(+14.9%) |
| Dec 2021 | $187.94 M(+560.1%) | $161.84 M(>+9900.0%) | $187.94 M(+594.9%) |
| Sep 2021 | - | $185.20 K(-99.2%) | $27.05 M(-5.1%) |
| Jun 2021 | - | $23.99 M(+1144.0%) | $28.50 M(+4.0%) |
| Mar 2021 | - | $1.93 M(+104.2%) | $27.40 M(-3.8%) |
| Dec 2020 | $28.47 M(-74.9%) | $944.20 K(-42.2%) | $28.47 M(+3.4%) |
| Sep 2020 | - | $1.63 M(-92.9%) | $27.53 M(+1.7%) |
| Jun 2020 | - | $22.89 M(+661.7%) | $27.06 M(+80.4%) |
| Mar 2020 | - | $3.00 M(+157.4%) | $15.00 M(-18.1%) |
| Dec 2019 | $113.64 M(+550.3%) | - | - |
| Sep 2019 | - | $1.17 M(-89.2%) | $18.32 M(+4.9%) |
| Jun 2019 | $17.48 M | $10.83 M(+560.8%) | $17.48 M(+153.2%) |
| Mar 2019 | - | $1.64 M(-65.0%) | $6.90 M(+32.6%) |
| Dec 2018 | - | $4.69 M(+1367.0%) | $5.21 M(+79.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $319.50 K(+24.2%) | $2.91 M(-55.6%) |
| Jun 2018 | $6.54 M(-2490.5%) | $257.30 K(-553.8%) | $6.54 M(+4.6%) |
| Mar 2018 | - | -$56.70 K(-102.4%) | $6.26 M(+0.4%) |
| Dec 2017 | - | $2.39 M(-39.7%) | $6.23 M(+64.4%) |
| Sep 2017 | - | $3.96 M(<-9900.0%) | $3.79 M(-1485.7%) |
| Jun 2017 | -$273.70 K(+3.8%) | -$27.60 K(-66.5%) | -$273.60 K(+11.2%) |
| Mar 2017 | - | -$82.40 K(+51.5%) | -$246.00 K(-2.4%) |
| Dec 2016 | - | -$54.40 K(-50.2%) | -$252.10 K(-11.7%) |
| Sep 2016 | - | -$109.20 K(<-9900.0%) | -$285.60 K(+8.3%) |
| Jun 2016 | -$263.80 K(-102.0%) | $0.00(-100.0%) | -$263.70 K(+2.4%) |
| Mar 2016 | - | -$88.50 K(+0.7%) | -$257.40 K(+30.7%) |
| Dec 2015 | - | -$87.90 K(+0.7%) | -$197.00 K(-102.2%) |
| Sep 2015 | - | -$87.30 K(-1485.7%) | $8.91 M(-32.3%) |
| Jun 2015 | $13.16 M(-45.7%) | $6300.00(-122.4%) | $13.16 M(+0.0%) |
| Mar 2015 | - | -$28.10 K(-100.3%) | $13.15 M(-0.2%) |
| Dec 2014 | - | $9.02 M(+116.8%) | $13.18 M(+216.8%) |
| Sep 2014 | - | $4.16 M(>+9900.0%) | $4.16 M(>+9900.0%) |
| Jun 2014 | $24.21 M(>+9900.0%) | - | - |
| Feb 2014 | - | $0.00(0.0%) | $20.00 K(0.0%) |
| Nov 2013 | - | $0.00(-100.0%) | $20.00 K(0.0%) |
| Aug 2013 | $20.00 K(+48.1%) | $20.00 K(>+9900.0%) | $20.00 K(>+9900.0%) |
| May 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 2012 | - | $0.00 | $0.00 |
| Aug 2012 | $13.50 K | - | - |
FAQ
- What is Relmada Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Relmada Therapeutics?
- What is Relmada Therapeutics annual CFF year-on-year change?
- What is Relmada Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Relmada Therapeutics?
- What is Relmada Therapeutics quarterly CFF year-on-year change?
- What is Relmada Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Relmada Therapeutics?
- What is Relmada Therapeutics TTM CFF year-on-year change?
What is Relmada Therapeutics annual cash flow from financing activities?
The current annual CFF of RLMD is -$98.50 K
What is the all time high annual CFF for Relmada Therapeutics?
Relmada Therapeutics all-time high annual cash flow from financing activities is $187.94 M
What is Relmada Therapeutics annual CFF year-on-year change?
Over the past year, RLMD annual cash flow from financing activities has changed by -$45.12 M (-100.22%)
What is Relmada Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RLMD is -$89.60 K
What is the all time high quarterly CFF for Relmada Therapeutics?
Relmada Therapeutics all-time high quarterly cash flow from financing activities is $161.84 M
What is Relmada Therapeutics quarterly CFF year-on-year change?
Over the past year, RLMD quarterly cash flow from financing activities has changed by -$311.30 K (-140.41%)
What is Relmada Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RLMD is $33.60 K
What is the all time high TTM CFF for Relmada Therapeutics?
Relmada Therapeutics all-time high TTM cash flow from financing activities is $215.96 M
What is Relmada Therapeutics TTM CFF year-on-year change?
Over the past year, RLMD TTM cash flow from financing activities has changed by -$89.60 K (-72.73%)